Pharmafile Logo

PHARMA POST COVID-19: REVOLUTION OR EVOLUTION?

- PMLiVE

Post-COVID-19 thinking: outputs from a thought leader forum

On 14 May 2020, a group of industry experts across pharma and biotech Zoomed together to share reflections on the impact of COVID-19 so far and the implications for how we should evolve in the coming months and years:
Download full article here

EXECUTIVE SUMMARY

Biggest impact of COVID-19

  • COVID-19 has had a significant impact on how the industry works; maintaining individuals’ well-being and finding the best ways to integrate digital has challenged many companies
  • Clinical trials have been affected, in particular, recruitment and progress. It was also noted that certain metrics and data collection are likely to be affected and may have an impact on future regulatory submissions
  • Our forum concluded that in general we expect sales of established medicines to be above expectations, with newer therapies likely to be behind budget, due mainly to patients not attending clinic and a reduced new/switched/repeat dynamic

Biggest concerns

  • We highlighted concern that future pricing may be affected. Government debt has been affected by COVID-19 and this may impact future pricing negotiations and also see a quicker transition to outcomes-based pricing
  • Our recommendation is that the industry needs to continue to build trust. Vaccine and COVID-19 treatment costs will be high-profile negotiations and may affect reputation or profits.
  • There is an opportunity for the industry to transition its reputation from medicines developers to healthcare providers
  • The industry needs to evolve how it works digitally, but we don’t expect a revolution, rather a gradual upskilling of organisations and of its people to enable more effective working. How this is done, however, is still uncertain, and is an opportunity for better collaboration

Biggest opportunities

  • We concluded that re-shaping how the field force evolve and work is a huge opportunity for the industry to add more value to society. How to add value through a truly multi-channel approach is an exciting opportunity for our industry, and a key opportunity for future discussion
  • The industry has spent millions on congress attendance for so many years. How the industry has recently operated offers an opportunity to re-think how to engage with congresses, but more importantly how to engage with healthcare professionals throughout the year. We don’t see a time when congresses are not important, but whether medical communications are anchored to congresses in the future is an opportunity to explore
  • It’s difficult to predict the new normal, but we know digital and user experience will be critical to effective commercialisation. This provides an exciting opportunity for our industry to create compelling digital experiences for brand and organisations to communicate with their audiences
  • We expect increased pricing pressure in the future. The organisations that adapt best, by providing real-world evidence, outcomes-based evidence and pricing, and support service re-design, will lead the future industry

Download full article here

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrates summer in style at their annual summer meeting

Lucid held their annual Summer Meeting last week. The event is all about taking the time out to celebrate colleagues, teams, and all they have achieved in the year so...

Data Visualisation

Last week’s Thirsty Thursday was all about data visualisation and was hosted by Katherine Mantell, Managing Director of Leading Edge – part of the Lucid family of companies.Katherine started the session with...

The True Potential of Mobile Health Tech

In a recent edition of PME, Dennis O’Brien, Lucid CEO and co-founder, discusses the potential of mobile health in improving patient outcomes – a goal that is at the heart...

Lucid’s magic touch is recognised, winning both Communiqué Medical Education Consultancy of the Year and Communiqué Communications Consultancy of the Year 2018

Lucid’s pioneering and patient-centric approach to strategic medical communications was recognised yesterday as they scooped  a total of four awards. These included: Excellence in Communications via Meetings for OptiMiSe –...

Improving Outcomes - Patient Engagement & Activation

Last week, Lucid launched its first Thirsty Thursday session, during which everyone gets an opportunity to quench their thirst for knowledge and learn about new industry trends and techniques. Last...

Patient outcomes in practice: delivering value that transforms lives

In this month’s PME, Lucid CEO and co-founder, Dennis O’Brien, and Managing Director, Louise Verrall, discuss ‘Patient outcomes in practice: delivering value that transforms lives’. In response to the increasing...

Lucid are bringing magic to the North West with three new hires

Lucid Group are spreading their magic to the North West with three new hires, bolstering their client services and delivery teams. Helen Hutton is appointed as Business Unit Director for...

Lucid's Right Royal Bake-Off

Lucid joined in on the royal wedding fervour today by celebrating the impending nuptials with a Royal Bake-off, producing cakes fit for the Queen and the new Princess. Lucid love...

Lucid’s magic touch is recognised as they make the shortlist in five different categories for Communiqué 2018

Lucid has been working its magic with its clients again!Four of their pioneering programmes have been shortlisted as finalists for this year’s Communiqué awards. And they have been shortlisted for...